Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3 study to evaluate the safety and efficacy of T-2345 dosed to one of both
eyes once daily for 84 days compared to Xalatan dosed to one of both eyes once daily for 84
days in patients with elevated eye pressure.